During the opening segment of this panel discussion about recent advances and pharmacoeconomic considerations in the clinical management of Castration-Resistant Prostate Cancer (CRPC), discussion moderator Raoul S. Concepcion, MD, is joined by expert panelists David Crawford, MD, Jeffrey D. Dunn, PharmD, MBA, Michael Kolodziej, MD, and David Quinn, MD.
After the panelists briefly introduce themselves and explain their relationships to medical oncology, Dr Concepcion cites important statistics about the economic and clinical burden of CRPC.
Dr Quinn reviews the treatment landscape for CRPC and explains how a paradigm shift in the US Food and Drug Administration’s approval of agents to treat CRPC has improved the disease’s outlook.
Balancing Life and Myeloma: A Patient-Centered Approach
November 22nd 2024In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.
Read More